Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Triamcinolone
Drug ID BADD_D02271
Description Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis.[L8255] Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain,[L8264] or first line as a topical treatment of corticosteroid responsive dermatoses.[L8249] Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957.[L8243] In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval[L38973] - for the treatment of patients with macular edema associated with uveitis.[L38963]
Indications and Usage For the treatment of perennial and seasonal allergic rhinitis.
Marketing Status Discontinued
ATC Code A01AC01; C05AA12; D07AB09; D07XB02; H02AB08; R01AD11; R03BA06; S01BA05
DrugBank ID DB00620
KEGG ID D00385
MeSH ID D014221
PubChem ID 31307
TTD Drug ID D03BLF
NDC Product Code 22552-0003; 46439-8701; 38779-0051; 51927-1049
Synonyms Triamcinolone | Volon | Aristocort
Chemical Information
Molecular Formula C21H27FO6
CAS Registry Number 124-94-7
SMILES CC12CC(C3(C(C1CC(C2(C(=O)CO)O)O)CCC4=CC(=O)C=CC43C)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Malignant melanomaSerotransferrinP02787T026173015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
Malignant melanomaInsulinP01308T828413015380; 2737997; 3919942; 6850583; 2788234; 2788497; 3297308; 6424929; 2439521; 6454570; 3049518; 6983291; 8826092; 6273246
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Seizure17.12.03.001--
Sepsis11.01.11.0030.000033%
Shock24.06.02.002--Not Available
Sinus congestion22.04.06.001--Not Available
Skin atrophy23.01.05.0010.000126%
Skin discolouration23.03.03.0050.000126%Not Available
Skin disorder23.03.03.0070.000443%Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin hypopigmentation23.05.02.0030.000190%
Skin striae23.01.05.002--Not Available
Sneezing22.02.05.011--
Spinal compression fracture12.04.04.001; 15.08.05.004; 14.04.04.003--Not Available
Subcutaneous abscess23.09.04.003; 11.01.12.0070.000190%Not Available
Swelling08.01.03.0150.000632%Not Available
Swelling face23.04.01.018; 10.01.05.0180.000126%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.000253%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tachycardia02.03.02.0070.000190%Not Available
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Thirst14.03.02.007; 08.01.09.0210.000126%Not Available
Thrombophlebitis24.01.02.001--Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000190%
Tooth disorder07.09.05.001--Not Available
Toothache07.09.06.0010.000126%
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urticaria10.01.06.001; 23.04.02.0010.000253%
Vaginal haemorrhage21.08.01.001; 24.07.03.0050.000190%
Vascular purpura24.07.06.011; 23.06.01.008; 01.01.04.007--Not Available
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages